leisure time -WSS

leisure time

author：explore 2025-09-30 15:23:04 - browse：4638

Novo Nordisk headquarters -- health coverage from STAT — Novo Nordisk's headquarters, outside Copenhagen, Denmark. LISELOTTE SABROE/Scanpix/AFP via Getty Images

Novo Nordisk is pausing ads for its obesity drug Wegovy as it struggles to keep up with surging demand, the latest hurdle in its rollout of the weight loss drug.

“To avoid stimulating further demand for this medicine, we’re pausing some key Wegovy promotional efforts,” the Danish drugmaker said in an emailed statement. “We are pausing all local television advertising and postponing planned national television advertising for Wegovy. We are also assessing our promotional efforts to healthcare professionals and adjusting accordingly.” The news was earlier reported by Endpoints.

Wegovy, which contains the active ingredient semaglutide, has become immensely popular for its effectiveness in helping people lose weight and is helping usher in what many see as a sea change in obesity treatment. Its sister drug for diabetes, Ozempic, has also been in demand for a similar effect on weight loss.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： 'Vaccine

knowledge

WSS

340B reform proposal comes out of Senate working group

Surgery pushed Ben Carson to fame

The CDC's new social media misinformation war

Laying a path for careers in science

Medicare Advantage isn’t working — for anyone

What’s missing from the debate over nursing home staff minimums

leisure time

leisure time

entertainment

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

The Biogen Aduhelm mess could happen again

In Memoriam: Notable people who died in 2023

Elisabeth Bik tackles the widespread issue of research misconduct

United colonoscopy coverage change 'may cost lives,' doctors say

Medicare Advantage plans can’t deny care with AI, CMS warns

Affirmative action in medical school literally saved lives

Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

Hollywood unions extend contract negotiations for actors

A protest over insulin prices is seen as a fight for life

hotspot

Covid overtakes 1918 Spanish flu as deadliest disease in U.S. history

NEJM study measures Covid brain fog, impact on IQ

The Biogen Aduhelm mess could happen again

Medicare isn't yet testing food as medicine

Why Novartis is going to walk from its acquisition of MorphoSys

Laying a path for careers in science

focus

knowledge

entertainment

focus